This FY 2018 Malaria Operational Plan (MOP) presents a detailed implementation plan for Ethiopia, based on the strategies of PMI and the National Malaria Control Program (NMCP). It was developed in consultation with the Federal Ministry of Health (FMOH), NMCP, Ethiopian Public Health Institute (EP...HI), and regional health bureaus, and with the participation of national and international partners involved in malaria prevention and control in the country. The activities that PMI is proposing to support align with the National Malaria Strategic Plan (NMSP 2014-2020) and build on investments made by PMI and other partners to improve and expand malaria-related services, including the Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund) malaria grants. This document briefly reviews the current status of malaria control policies and interventions in Ethiopia, describes progress to date, identifies challenges and unmet needs to achieving the targets of the NMCP and PMI, and provides a description of activities that are planned with FY 2018 funding.
more
National estimates have been developed every two years since 2003, led by the NCASC with close collaboration from a range of technical experts, partners and epidemiologists from the UNAIDS, WHO and FHI. This contains information about estimations of adult HIV prevalence.
Lancet Neurol. Volume 18, ISSUE 5, P439-458, May 01, 2019
Published Mar 11. pii: S1474-4422(19)30034-1. doi: 10.1016/S1474-4422(19)30034-1.
Pre-exposure prophylaxis (PrEP)
Policy Brief
November 2015
Dengue is a mosquito-borne viral disease that has rapidly spread to all regions of WHO in recent years. Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae. albopictus. These mosquitoes are also vectors of chikungunya, yellow fever and Zik...a viruses. Dengue is widespread throughout the tropics, with local variations in risk influenced by climate parameters as well as social and environmental factors.
more
Plos Current Outbreaks November 21, 2014
J. European Academy of Dermatology and Venereology, 4 August 2014
Updated March 2018 | Accessed Online March 2018
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx